Thalidomide enantiomers: Determination in biological samples by HPLC and vancomycin-CSP

Murphy-Poulton, Susan F.; Boyle, Frances; Gu, Xiao; Mather, Laurence E.

doi:10.1016/j.jchromb.2005.11.023

Cited by 23 publications

(14 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In analytical methods, thalidomide stability is also recognised as a problem but the majority of authors listed in Table 1 have addressed the issue of thalidomide hydrolysis through sample acidification prior to storage. A variety of sample clean-up methods have also been applied including SPE [16] and PPT [17][18][19][20] and LLE [21], though Saccomanni et al [18] and Yang et al [19] used the samples preparation method developed by Zhou et al [20]. A summary of the method outlined in this research, and methods previously published in the literature for the analysis of thalidomide in biological matrices, are compiled in Table 1.…”

Section: Introductionmentioning

confidence: 99%

Development, validation and application of a sensitive LC–MS/MS method for the quantification of thalidomide in human serum, cells and cell culture medium

Roche

Sewell

Meiller

et al. 2012

Journal of Chromatography B

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Development, validation and application of a sensitive LC–MS/MS method for the quantification of thalidomide in human serum, cells and cell culture medium

Roche

Sewell

Meiller

et al. 2012

Journal of Chromatography B

View full text Add to dashboard Cite

“…Although serum samples with equal volumes of citrate buffer (pH 2, 0.2 M) are stable in storage at Ϫ80°C, 19) the acidified whole blood sample with citrate buffer (pH 1.5, 25 mM) was stable in storage at Ϫ30°C within 75 d. 20) Thus, we chose the method by Eriksson and Björkman. Instead of extraction with organic solvents, we used a direct deproteinization method.…”

Section: Resultsmentioning

confidence: 99%

A New Method for Determination of Both Thalidomide Enantiomers Using HPLC Systems

Sembongi

Tanaka²,

Sakurada³

et al. 2008

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Over the last few years, thalidomide has become one of the most important anti-tumour drugs for the treatment of relapsed-refractory multiple myeloma. However, besides its undesirable teratogenic side effect, its configurational instability critically limits any further therapeutic improvements of this drug. In 1999, we developed fluoro-thalidomide which is a bioisostere of thalidomide, but, in sharp contrast to the latter, it is configurationally stable and readily available in both enantiomeric forms. The biological activity of fluoro-thalidomide however, still remains virtually unstudied, with the exception that fluoro-thalidomide is not teratogenic. Herein, we report the first biological evaluation of fluoro-thalidomide in racemic and in both (R)-and (S)-enantiomerically pure forms against (in vitro) H929 cells of multiple myeloma (MM) using an annexin V assay. We demonstrate that all fluoro-thalidomides inhibited the growth of H929 MM cells without any in-vivo activation. Furthermore, we report that the enantiomeric forms of fluoro-thalidomide display different anti-tumour activities, with the (S)-enantiomer being noticeably more potent. The angiogenesis of fluoro-thalidomides is also investigated and compared to thalidomide. The data obtained in this study paves the way towards novel pharmaceutical research on fluoro-thalidomides.

show abstract

“…In general, the side effects of drugs might be induced by the (+)-S-CB enantiomer 7) or by the misuse of drugs. In Fig.…”

Section: Discussionmentioning

confidence: 99%

“…CB is manufactured as a 1:1 racemic mixture (rac-CB) of two enantiomers, (-)-R and (+)-S isomers, and it is generally believed that only the (-)-R enantiomer shows pharmacological activity. It is important to make clear the different actions of enantiomers as seen in the case of the Thalidomide Tragedy 7) . For the first time, von Deutsch et al 8) reported that both enantiomers had equal anabolic activity in skeletal muscle of mature male rats, but was less active in cardiac muscle hypertrophy than rac-CB.…”

Section: Introductionmentioning

confidence: 99%

Effects of clenbuterol enantiomers on growth of young male rats

Kitaura

Kraemer

2015

JPFSM

View full text Add to dashboard Cite

Clenbuterol (CB) is one of the β 2 -adrenergic receptor agonists with powerful muscle anabolic and lipolytic effects, and is prohibited as a doping drug for athletes. However, it is one of the candidate countermeasures for aging-related diseases. Previously we reported that CB induced muscular hypertrophy, but inhibited the longitudinal growth of bones in young male rats. However, the mechanism of the inhibitory effect on bone growth is not yet clear. CB is manufactured as a 1:1 racemic mixture of 2 isomers of (-)-R and (+)-S enantiomers, and only the (-)-R enantiomer may have pharmacological activity. We examined the effects of two CB enantiomers, (+)-S-CB and (-)-R-CB, on growth of striated muscle and bone in young male rats. Eighteen male Sprague-Dawley rats (8-wk-old) were randomly assigned to a control (CONT, n = 6) and two CB enantiomers groups ((+)-S-CLEB: n=6, (-)-R-CLEB: n=6). Each CB enantiomer of 2 mg/kg body weight was daily administered subcutaneously for 2 weeks. After treatment, heart and the slow-twitch soleus (SOL) and fast-twitch extensor digitorum longus (EDL) muscles and bones were analyzed. The muscle wet weights of SOL and EDL muscles significantly increased in (+)-S-CLEB (HEART: +28%, SOL: +25%, EDL: +28%) and (-)-R-CLEB (HEART: +27%, SOL: +29%, EDL: +35%). Both (+)-S-CB and (-)-R-CB induced striated muscle hypertrophy (heart, SOL, and EDL). Concerning bones, (+)-S-CB induced decreased tibia length (-1.2%) and decreased femur BMD (-5.8%), and (-)-R-CB induced decreased femur BMD (-8.2%). These results show that (+)-S-CB and (-)-R-CB might work differently at times.

show abstract

Thalidomide enantiomers: Determination in biological samples by HPLC and vancomycin-CSP

Cited by 23 publications

References 37 publications

Development, validation and application of a sensitive LC–MS/MS method for the quantification of thalidomide in human serum, cells and cell culture medium

Development, validation and application of a sensitive LC–MS/MS method for the quantification of thalidomide in human serum, cells and cell culture medium

A New Method for Determination of Both Thalidomide Enantiomers Using HPLC Systems

Effects of clenbuterol enantiomers on growth of young male rats

Contact Info

Product

Resources

About